AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Status:
Completed
Trial end date:
2017-04-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of
daily living, resource utilization, quality of life, pharmacokinetic measures and safety
among participants with mild to moderate Alzheimer's Disease.